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Abstract
Introduction Sentinel lymph node (SLN) biopsy allows
identification of the first lymph node into which a primary tumor
drains. In breast cancer, identification of tumor cells in the SLNs
is a predictor of the tumor's metastatic potential. In the present
article, we tested the hypotheses that a positive immune
response can occur in tumor-free SLNs and that the activation
state of dendritic cells (DCs), the major antigen presenting cells
within SLNs, predicts the immune status and metastatic
potential of the tumor.
Methods Fifty paraffin-embedded SLN sections, 25 tumor-free
and 25 tumor-containing, from patients with breast cancer were
analyzed by immunohistochemistry to determine the immune
maturation state of their DCs. In addition, 12 lymph nodes from
noncancer-containing breasts were analyzed. Tissues were
stained with antibodies against CD3, MHC class II, CD1a,
CD83, IL-10, and IL-12. Mature DCs were defined by CD83
expression and immature DCs by CD1a expression.
Results We found a trend toward higher numbers of mature
CD83-positive DCs in tumor-free SLNs than in tumor-containing
SLNs (P = 0.07). In addition, tumor-free SLNs were more likely
to contain cells expressing IL-10 (P = 0.02) and, to a lesser
extent, IL-12 (P = 0.12). In contrast, when all SLNs, both tumor-
free and tumor-containing, were compared with uninvolved
lymph nodes, the numbers of mature and immature DCs were
similar.
Conclusions Our results suggest tumor-free SLNs are
immunologically competent and potentially a site of tumor-
specific T-cell activation, as evidenced by the presence of
greater numbers of mature DCs and cytokine-producing cells in
tumor-free SLNs.
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Introduction
Tumor-specific T-cell activation begins in the primary tumor
when dendritic cells (DCs) encounter antigens in the form
of apoptotic or necrotic tumor cells. The DCs engulf dying
tumor cells and process their antigens into peptides that
are presented in the context of MHC class I and class II
molecules [1,2]. The function of a DC is highly influenced
by its level of maturation. Immature DCs are capable of anti-
gen uptake and processing but cannot, unless given the
proper cytokine signals, present antigen to T cells [1,3,4].
After receiving the correct cytokine signals, the mature,
peptide-loaded DCs migrate from the tumor to the first
draining lymph node, referred to as the sentinel lymph node
(SLN). In the SLN, naïve T cells are activated by the pep-
tide-loaded mature DCs. These T cells then undergo clonal
expansion, gain effector function, and circulate back to the
tumor, where their function is to lyse tumor cells. Evidence
to support this process comes almost entirely from in vitro
experiments [1-4].
SLN biopsy allows identification of the first lymph node into
which a primary tumor drains. In breast cancer, identifica-
tion of tumor cells in the SLNs is a predictor of the tumor's
metastatic potential [5,6]. In the present study, we exam-
ined SLNs for evidence of immune activation by examining
the maturation state of DCs within the SLNs. We defined
mature DCs by their expression of the marker CD83 [7,8],
while immature DCs were identified by their expression of
the marker CD1a. We were interested in determining
whether the maturation status of DCs in SLNs was
DC = dendritic cell; H & E = hematoxylin and eosin; hpf = high-powered field; IL = interleukin; MHC = major histocompatibility complex; PBMC = 
peripheral blood mononuclear cell; SLN = sentinel lymph node; Th = T helper cell.Breast Cancer Research    Vol 6 No 4    Poindexter et al.
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associated with the tumor status of the SLN, so we com-




SLN tissues from women aged 26–87 years who had a
SLN biopsy performed at The University of Texas MD
Anderson Cancer Center between 1998 and 2001 were
included in the study. Each of the patients had received a
diagnosis of breast cancer and had undergone SLN biopsy
as part of her surgical treatment. Paraffin-embedded SLN
tissues from 50 patients, 25 with tumor-free SLNs and 25
with tumor-containing SLNs, were examined. The tumor
status of the SLN was determined by H & E and immuno-
histochemical staining. All samples were banked in the
Breast Tumor Bank at The University of Texas MD Ander-
son Cancer Center.
The study population included six women who received
chemotherapy prior to their SLN biopsy: four whose SLNs
contained tumors and two whose SLNs were tumor-free.
Twelve lymph nodes draining from the unaffected breast of
women with breast cancer were similarly processed. All
materials were collected under a protocol approved by the
MD Anderson Cancer Center Institutional Review Board.
Antibodies
The following antibodies were used for immunohistochem-
ical staining: anti-CD3 (clone PS1; BioGenex, San Ramon,
CA, USA), anti-HLA class II (clone CR3/43; DAKO,
Carpinteria, CA, USA), anti-CD83 (clone HB15A; Immu-
notech, Marseille, France), anti-CD1a (clone O10; Immu-
notech), anti-IL-10 (clone 23738.111; R & D Systems,
Minneapolis, MN, USA), and anti-IL-12 (clone 24910.1; R
& D Systems). Optimal concentrations were determined
empirically, and all antibodies were tested for staining of
cells in cytospin preparations of peripheral blood mononu-
clear cell (PBMC)-derived immature DCs (PBMCs stimu-
lated with granulocyte–macrophage colony-stimulated
factor and IL-4 for 6 days) or mature DCs (PBMCs stimu-
lated with granulocyte–macrophage colony-stimulated fac-
tor and IL-4 for 6 days followed by tumor necrosis factor
alpha for 24 hours).
Immunohistochemistry
Tissue sections, 3 µm thick, were cut from tissue blocks of
formalin-fixed, paraffin-embedded SLNs. Immunocyto-
chemical staining of deparaffinized, fixed slides was per-
formed after antigen retrieval by microwave heating in
citrate buffer. Slides were incubated with biotinylated goat
anti-mouse IgG followed by avidin–biotin–peroxidase com-
plex (Vectastain ABC Kit; Vector Laboratories, Berlingame,
CA, USA). The peroxidase was developed by 3-amino-9-
ethylcarbazole-9 (AEC substrate kit; Vector Laboratories)
and counterstained with Gill's hematoxylin (Vector Labora-
tories). Isotype-matched antibodies were used as negative
controls. The positive control antibody for each group of
slides was anti-CD3.
Because of the localized distribution of DCs within the
SLNs, each slide was scored by counting positively stained
cells in five high-powered fields (hpfs) under × 400 magni-
fication. Results were reported for each SLN as the mean
± standard error of the mean for 5 hpfs. This method has
been used by other workers when analyzing the expression
of mature DCs in breast tissue [2,9]. All slides were
counted without knowledge of the SLN status, and results
were confirmed through a second reading by a breast can-
cer pathologist (AS).
Statistical analysis
All data sets were tested for normal distribution. Because
most data groups were not normally distributed, all data
groups were analyzed by the Wilcoxon rank sum test. P <
0.05 was considered significant.
Results
Clinicopathologic characteristics of the patient 
population
Table 1 presents the clinicopathologic characteristics of
the patients whose SLNs were included in this study.
Patients ranged from 26 to 87 years of age at the time of
diagnosis. No significant difference in median age distin-
guished the tumor-free SLN and the tumor-containing SLN
groups (56 and 55 years, respectively). Additionally, we
examined the estrogen receptor and progesterone recep-
tor status, the size, grade, and the stage of disease of the
tumors. There were no remarkable differences between the
two groups of patients.
Comparison of mature and immature DCs within the SLN
SLNs were examined for cells expressing CD83 and CD1a.
Immature DCs, characterized by the expression of CD1a,
were generally found in the paracortical areas of the SLNs.
CD1a-expressing cells with typical DC morphology were
found in 49 of 50 SLNs examined, with a median of 55
cells/hpf (range, 0–123 cells/hpf). Mature DCs expressing
CD83 were found in 47 of 50 SLNs, with a median of 7
cells/hpf (range, 0–38 cells/hpf). Figure 1 shows the pat-
terns of CD83 and CD1a expression in a tumor-free SLN
and a tumor-containing SLN, respectively. At the magnifica-
tion shown (× 400), the different staining patterns are
apparent, with the antibody to CD1a staining more dendri-
form cells than the CD83 antibody, which stains cells with
much shorter dendrites. Another interpretation is that the
CD83 antibody stains both membranous and cytoplasmic
CD83, whereas the CD1a antibody stains only the mem-
branous CD1a. Figure 2 shows sequential slides from the
same paraffin block stained with the antibody to CD3,Available online http://breast-cancer-research.com/content/6/4/R408
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MHC class II, CD1a, and CD83. These slides are
representative of the SLNs identified as tumor-free. The
CD83-positive cells were found surrounding the paracorti-
cal T-cell areas, usually near the sinuses of the SLNs.
Although double staining was not performed, examination
of sequential sections stained with anti-CD83 and anti-
MHC class II antibodies strongly suggested that the cells
staining positively for CD83 were also positive for MHC
class II.
When SLNs were compared by tumor burden, it was found
that tumor-free SLNs contained a higher number of CD83-
positive cells than tumor-containing SLNs. The numbers of
CD1a-positive cells within these two groups of SLNs were
similar. Figure 3 shows the comparison between the num-
bers of CD1a and CD83 DCs in tumor-free and tumor-con-
taining SLNs. There was a trend (P = 0.07) toward higher
numbers of CD83-positive, mature DCs in tumor-free SLNs
(median, 10.4 cells/hpf) than in tumor-containing SLNs
(median, 4.5 cells/hpf). The numbers of CD1a-positive
immature DCs did not differ between the tumor-free and
tumor-containing SLNs (P = 0.93).
Comparison of clinicopathologic features of the tumor 
and DCs in the SLN
When tumors were analyzed based on hormone receptor
status or tumor size, the numbers of CD83-expressing or
CD1a-expressing cells in tumor-free and tumor-containing
SLNs were not significantly different (data not shown).
Notably, however, when tumors were sorted by nuclear
grade and SLN status, we found that the number of CD1a-
positive, immunologically immature DCs was significantly
greater (P = 0.01) in the tumor-containing SLNs draining
from grade III tumors than in the tumor-free SLNs draining
from grade III tumors (Table 2). These data suggest that the
differentiation status of the tumor affected the maturation of
the DCs within the tumor.
Cytokine expression in the SLN
Pivotal cytokines in the generation of a Th1 response ver-
sus a Th2 response are IL-10 and IL-12. DCs will respond
to these cytokines and become polarized toward activating
Th1 and Th2 [10]. We examined the SLNs for these two
cytokines to determine whether there was an indication of
this activation. An analysis of cytokine-expressing cells is
Table 1
Clinicopathologic features associated with sentinel lymph nodes (SLNs)








Estrogen receptor-positive 17 (68%)a 19 (76%)
Estrogen receptor-negative 4 (16%) 6 (24%)
Unknown 4 (16%) 0
Progesterone receptor-positive 15 (60%) 18 (72%)
Progesterone receptor-negative 5 (20%) 7 (28%)
Unknown 5 (20%) 0
Tumor grade
Grade I 3 (12%) 3 (12%)
Grade II 11 (44%) 12 (48%)
Grade III 8 (32%) 8 (32%)
Unknown 3 (12%) 2 (8%)
a Data presented as number (percentage of total number of SLNs in each category).Breast Cancer Research    Vol 6 No 4    Poindexter et al.
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shown in Fig. 4. Tumor-free SLNs contained higher num-
bers of IL-10-producing cells (P = 0.02) and IL-12-produc-
ing cells (P  = 0.12). Examination of sequential slides
stained with anti-MHC class II or DC antibodies suggested
that the cytokine-positive cells were MHC class II-positive
and CD83-positive (Fig. 2). Tumor cells expressing IL-10
were not found in any of the SLNs examined.
Comparison of SLN and lymph nodes draining from 
noncancer-containing breasts
To understand whether the numbers of DCs seen in the
SLNs were indicative of an activated state due to the pres-
ence of tumor, we examined 12 lymph nodes draining from
the uninvolved noncancer-containing breast of patients
with breast cancer (uninvolved lymph nodes) and com-
pared them with the 50 SLNs from the breast cancer
patients already analyzed. The numbers of CD1a-positive
cells and CD83-positive cells were not significantly differ-
ent when these uninvolved lymph nodes were compared
with SLNs as a group (Fig. 5a,5b). In addition, when the
number of CD83-positive cells in the tumor-free and tumor-
containing SLNs were compared with the number of
CD83-positive cells in the uninvolved lymph nodes, the
tumor-free SLNs were very similar to the uninvolved lymph
nodes (Figs 3 and 5). When cytokine-expressing cells were
examined, SLNs contained significantly higher numbers of
both IL-10-expressing cells (P = 0.02) and IL-12-express-
ing cells (P = 0.002) than the uninvolved lymph nodes (Fig.
5c,5d). Although the numbers of cytokine-expressing cells
in both groups were low, the cytokine expressing cells were
more abundant in the tumor-free SLNs.
Discussion
Our experiments were designed to determine whether the
SLN was the site of T-cell activation in breast cancer
patients. Identification of immunologically mature DCs
within the SLN would support this hypothesis. In our exper-
iments, mature DCs were defined by their expression of
CD83, a marker that has been shown on DCs capable of
antigen presentation and activation of naïve T cells [7,8].
Our results show a definite trend toward higher numbers of
CD83-positive DCs in tumor-free SLNs than in tumor-con-
taining SLNs. In addition, tumor-free SLNs contained signif-
icantly higher numbers of IL-10-expressing cells. Both of
these observations support the hypothesis that a tumor-
free SLN is immunologically competent and is potentially a
site of tumor-specific T-cell activation.
What remains unclear from our data is the type of immune
response that occurs in the tumor-free SLNs. Identification
of both IL-10-expressing and IL-12-expressing cells sug-
gests two possibilities. The existence of IL-10 in tumors has
been associated with immune suppression of a Th1
response and increased tumorigenicity [11]. But it has
been shown convincingly through in vitro studies that IL-10
specifically affects immature DCs by inhibiting upregulation
of MHC class II and costimulatory molecules and expres-
sion of CD83-positive cells. Mature CD83-expressing DCs
are resistant to the effects of IL-10 [12]. Less information is
available on the expression of IL-12 in tumor-draining lymph
Figure 1
Expression of CD83 in a tumor-free sentinel lymph node (SLN) and of  CD1a in a tumor-containing SLN from a breast cancer patient Expression of CD83 in a tumor-free sentinel lymph node (SLN) and of 
CD1a in a tumor-containing SLN from a breast cancer patient. Paraffin-
embedded (a) tumor-free or (b) tumor-containing SLN tissue was ana-
lyzed for expression of CD83 or CD1a, respectively, by immunohisto-
chemistry. Typical examples of dendritic cell morphology stained with 
each antibody are shown (magnification, × 400).
Figure 2
Expression of (a) CD3, (b) MHC class II, (c) CD1a, (d) CD83, (e) IL- 10, and (f) IL-12 in a tumor-free sentinel lymph node (SLN) from a  breast cancer patient analyzed by immunohistochemistry Expression of (a) CD3, (b) MHC class II, (c) CD1a, (d) CD83, (e) IL-
10, and (f) IL-12 in a tumor-free sentinel lymph node (SLN) from a 
breast cancer patient analyzed by immunohistochemistry. Sequential 
sections from one block are shown (magnification, × 200).Available online http://breast-cancer-research.com/content/6/4/R408
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nodes. Animal, as well as in vitro, studies support the role
of IL-12 as a proinflammatory cytokine that drives DCs
toward activation of Th1 [13,14]. Clearly, the existence of
both of these two cytokines in the SLN and not in unin-
volved lymph nodes supports the hypothesis that an active
immune response is occurring in the SLNs. Future func-
tional studies examining both DCs and T cells are needed
to determine whether the SLN is a site of immune
suppression, as suggested by the expression of IL-10, or of
immune activation, as suggested by expression of IL-12.
Our results differ from those reported by Huang and col-
leagues [15], who compared S-100-positive DCs in SLNs
and non-SLNs. Their conclusion, based on the morphology
and density of the paracortical area and the number of
paracortical S-100-positive DCs, was that the SLN was
immunomodulated compared with the non-SLN. The SLNs
examined in their study had reduced paracortical areas,
reduced densities of paracortical DCs, and reduced fre-
quencies of S-100-positive DCs with a predominance of
immature, poorly dendritic DCs. Because they did not iden-
tify the tumor-free SLNs versus the tumor containing SLNs
in their study, it is hard to compare our results with theirs.
When we group our data and compare all SLNs with lymph
Figure 3
Comparison of the numbers of (a) CD83-expressing cells and (b)  CD1a-expressing cells in tumor-free and tumor-containing sentinel  lymph nodes (SLNs) of breast cancer patients Comparison of the numbers of (a) CD83-expressing cells and (b) 
CD1a-expressing cells in tumor-free and tumor-containing sentinel 
lymph nodes (SLNs) of breast cancer patients. Each data point repre-
sents the mean number of cells per high-powered field (in five fields) 
(magnification, × 400) from a paraffin-embedded section analyzed by 
immunohistochemistry. The horizontal bars represent the median 
number for each group. A trend toward a greater number of CD83-
expressing cells in the tumor-free SLNs than in the tumor-containing 
SLNs was seen (P = 0.07); no difference in the number of CD1a-
expressing cells distinguished the two types of SLNs (P = 0.93).
Table 2
Comparison of CD83-expressing and CD1a-expressing dendritic 
cells in tumor-free and tumor-containing sentinel lymph nodes 
(SLNs) by tumor grades
Dendritic cellsa Tumor gradeb
Grade I Grade II Grade III
CD83-expressing cells
Tumor-free SLNs
Number 3 11 8
Mean (± SEM) 4.5 ± 4.5 10.2 ± 3.5 13.0 ± 2.9
Median 0 8 16.7
Range 0–13.4 0.4–38.4 0.4–21.8
Tumor-containing SLNs
Number 3 12 8
Mean (± SEM) 9.1 ± 2.7 4.9 ± 1.3 5.8 ± 1.8
Median 9.2 3.3 5.5
Range 4.4–13.6 0–14.2 0.6–15.4
P valuec 0.40 0.34 0.16
CD1a-expressing cells
Tumor-free SLNs
Number 3 11 8
Mean (± SEM) 57.9 ± 5.6 60.0 ± 10.5 49.0 ± 5.1
Median 63.2 63.5 48.6
Range 46.8–63.8 0–97.0 25.6–70.6
Tumor-containing SLNs
Number 3 12 8
Mean (± SEM) 59.0 ± 23.5 48.7 ± 8.5 80.0 ± 8.1
Median 53.2 41.6 74.3
Range 21.6–102.2 12.4–102.0 54.4–122.8
P value 1.0 0.41 0.01
SEM, standard error of the mean. a Number of cells per high-
powered field. b The grade was unknown for two tumors in the tumor-
containing SLN group and for three tumors in the tumor-free SLN 
group. c P values determined by the Wilcoxon rank sum test 
comparing the number of CD83-expressing or CD1a-expressing 
dendritic cells in tumor-free SLNs versus tumor-containing SLNs for 
each tumor grade.Breast Cancer Research    Vol 6 No 4    Poindexter et al.
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nodes draining from the noncancer-containing breast of
women with cancer, however, the numbers of DCs in the
SLNs and these lymph nodes are not different, suggesting
that the SLN is not immunomodulated compared with unin-
volved nodes.
Few laboratories have examined the immune status of
SLNs of human tumors [15-17]. Most work involving SLNs
has been limited to studies of frozen or paraffin-embedded
tissue. In one of the few studies in which fresh SLN tissue
was available, an attempt was made to determine whether
tumor-specific T cells could be categorized as Th1-type or
Th2-type cells, based on cytokine profiles [16]. No classifi-
cation was possible because the SLN T cells secreted both
interferon gamma and IL-10 when stimulated with autolo-
gous tumor cells. However, these T cells were clearly tumor
specific because they responded to autologous but not all-
ogeneic tumor cells [16]. A more recent study examining
the cytokines produced by Staphylococcal enterotoxin-A-
stimulated T cells from SLNs that drain primary melanoma
showed both Th1 and Th2 cytokines could be measured by
an enzyme-liked immunospot (ELISPOT) assay in tumor-
free SLNs, whereas tumor-containing SLNs showed no
increase in cytokine secretion [17]. The implication from
this study was that immune responses were downregulated
by micrometastases in the SLN. Both reports support our
data and suggest that the SLN is the site of antigen-spe-
cific activation and that the tumor status of the node may
predict the immune response to the tumor.
The pathologic features of the tumor may affect the immune
response in the SLN. It is accepted that the tumor microen-
vironment affects the maturation state of the DCs in the
tumor. Our data showed that the number of CD1a-express-
ing cells in the SLN was associated with tumor grade.
When high-grade tumors (grade III) were analyzed, higher
numbers of CD1a cells were found in the tumor-containing
SLNs. This suggested that the undifferentiated state of the
tumor inhibits DC maturation, causing an accumulation of
immature DCs unable to activate naïve T cells and resulting
in metastasis of the tumor to the draining node. A report by
Vitale and colleagues [18] suggested that the lack of an
immune response in the high-grade tumor is explained by
the downregulation of MHC class I and TAP-1 and TAP-2
proteins in these tumors.
A recent report by Iwamoto and colleagues [9] examining
CD83-expressing DCs in 130 human breast tumors
demonstrated that the presence of tumor-infiltrating CD83-
expressing DCs correlated inversely with lymph node
metastasis. Their data strongly suggested that CD83 DCs
are involved in the initiation of the primary antitumor
response. Our data, which showed a trend toward
increased numbers of CD83-positive DCs in tumor-free
SLNs compared with tumor-containing SLNs, further sup-
port this conclusion, and similarly suggest that the matura-
tion state of the DCs predicts the metastatic potential of
the tumor. Further experiments to compare the DCs in pri-
mary tumors and their SLNs are now underway in our labo-
ratory to confirm the relationship between the maturation
state of the DCs, the tumor grade, and the tumor metastatic
potential.
Conclusions
In summary, we found a trend toward higher numbers of
CD83-positive DCs in tumor-free SLNs than in tumor-con-
taining SLNs. In addition, tumor-free SLNs contain signifi-
cantly higher numbers of IL-10-expressing cells. Both of
Figure 4
Comparison of the numbers of (a) IL-10-expressing cells and (b) IL-12- expressing cells in tumor-free and tumor-containing sentinel lymph  nodes (SLNs) of breast cancer patients Comparison of the numbers of (a) IL-10-expressing cells and (b) IL-12-
expressing cells in tumor-free and tumor-containing sentinel lymph 
nodes (SLNs) of breast cancer patients. Each data point represents the 
mean number of cells per high-powered field (in five fields) (magnifica-
tion, × 400) from a paraffin-embedded section analyzed by immunohis-
tochemistry. The horizontal bars represent the median number for each 
group. A significantly greater number of IL-10-expressing cells were 
seen in the tumor-free SLNs than in the tumor-containing SLNs (median 
number, 7.4 versus 0; P = 0.02); a trend toward a greater number of IL-
12-expressing cells was seen in the tumor-free SLNs than the tumor-
containing SLNs (median number, 2.2 versus 0.5; P = 0.12).Available online http://breast-cancer-research.com/content/6/4/R408
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these observations support the hypothesis that the tumor-
free SLN is immunologically competent and is potentially a
site of tumor-specific T-cell activation. To establish the
prognostic potential of the DCs in the SLN, we are now
undertaking functional studies to compare the immune
status of DCs isolated from the primary tumors of patients
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